This amount reflects total healthcare system costs for initial breast, cervical, colorectal, lung and prostate cancer screening. The largest share of the total cost was CRC screenings via colonoscopy, accounting for $23.7 billion, or 55% of the total. All other CRC screenings combined accounted for another $3.8 billion.
Significantly, the study also found that the $43.2 billion total was less than the reported cost of cancer treatment within the first 12 months after diagnosis, an indication of the cost-effectiveness of early screening, according to the study.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.